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This issue’s Immunology Select discusses recent studies on allergic responses in mouse models of human dis-
ease as well as how certain drugs, like the glucocorticoid dexamethasone, alleviate the symptoms of allergy.
An Abundant and Unexpected Allergen
There are many similarities between the immune responses to allergens and to par-
asitic worms. In their new study, Reese et al. (2007) examined immune responses
in the lung tissue of mice infected with the helminth Nippostrongylus brasiliensis.
This parasitic worm migrates to the lung, where it molts and remodels its stiff
pharyngeal feeding tube made of the biopolymer chitin before ascending the trachea
and being swallowed, thereby enabling it to access the intestine. In this model of
infection, the mammalian proteins acidic chitinase AMCase and Ym1 and Ym2 (chi-
tinase-like proteins) are produced in response to the transcription factor Stat6. Reese
et al. determined that there is Stat6-mediated production of AMCase and Ym2 in the
lungs of mice at 3 days post worm infection. Given that AMCase is an enzymatically
active chitinase, yet mammals lack chitin, the authors next examined whether the
immune response could be mediated by the chitin discarded by the molting worms.
They administered chitin intranasally to introduce it into the lungs of mice, which re-
sulted in recruitment of eosinophils and basophils within 2 to 3 days. This recruitment
was abrogated by pretreatment of the chitin with enzymatically active AMCase. They
next generated mice that overexpressed AMCase constitutively in the lung. When
exposed to chitin, these mice had lowered inflammatory responses. Interestingly,
the recruitment of eosinophils and basophils is independent of Stat6 but is dependent
on the eosinophil chemoattractant leukotriene B4 secreted by macrophages. The authors go on to show that a spe-
cial type of macrophage (an alternatively activatedmacrophage) appears in the lung tissue upon exposure of mice to
chitin. The authors propose a model in which macrophages encountering chitin become alternatively activated and
secrete the chemoattractant leukotriene B4 in response to chitin in order to entice eosinophils to enter the tissue.
Subsequent production of AMCase in response to interleukin (IL)-4 and IL-13 produced by inflammatory cells
degrades the chitin, thereby attenuating the response. Given the ubiquitous nature of chitin in the environment
(it provides structural rigidity to fungi, crustaceans, and insects as well as worms and their eggs) and the incidence
of asthma in shellfish workers, chitin may be an important cause of allergy in humans.
T.A. Reese et al. (2007). Nature 447, 92–96. Published online April 22, 2007. 10.1038/nature05746.
The Complex Effects of Osteopontin
Xanthou et al. (2007) examine the role of the cytokine osteopontin (a well-known mediator of the Th1 immune
response) in the Th2 immune response induced in a mouse model of allergic airway inflammation. First, they
show that during allergic Th2 responses in this model, osteopontin expression is upregulated in the lung. In humans,
lung biopsies from asthma patients exhibit increased osteopontin expression in lung tissue. Therefore, the authors
next examined the mouse immune response in the absence of osteopontin, which they depleted using a neutralizing
antibody to this cytokine. Interestingly, they found that osteopontin has a proinflammatory function at sensitization
(first exposure to antigen), whereas it has an anti-inflammatory function during challenge (re-exposure to antigen).
During sensitization, blocking osteopontin results in reduced infiltration of leukocytes into the lung, decreased
mucus secretion, and reduced levels of interleukins (IL)-4, -13, -10 and the Th2-specific chemokine CCL22 (all
indicative of a lessened Th2 response). The authors found that these effects were due to an increased number of
plasmacytoid dendritic cells (pDCs), which suppress Th2 responses. During challenge with antigen, however,
mice injected with neutralizing antibodies to osteopontin exhibit enhanced Th2 responses, with increased numbers
of inflammatory cells and eosinophils in the lung and increased amounts of IL-4, -13, -10, and interferon (IFN)-g. The
enhanced Th2 response was due to the increased recruitment of conventional dendritic cells. Importantly,
administering osteopontin intranasally prior to challenge with antigen in the mouse model of allergic airway
inflammation resulted in decreased recruitment of immune cells to the lung and abrogation of the inflammatory
response.
G. Xanthou et al. (2007). Nat. Med. 13, 570–578. Published online April 15, 2007. 10.1038/nm1580.
The Ins and Outs of Mast Cells
The sphingolipid, sphingosine-1-phosphate (S1P), induces a Th2 immune response and causes an increase in
circulating IgE molecules resulting in enhanced release of histamines and other inflammatory molecules from
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mast cells. S1P is generated in many immune cell types, including mast cells by phosphorylation of sphingosine by
the sphingosine kinases, SphK1 or SphK2. Olivera et al. (2007) created mice lacking SphK1 and/or SphK2 to
evaluate how these kinases contribute to mast cell function. They found that SphK2 mediates mast cell responses
by regulating S1P production, mediating calcium ion influx, activating NF-kB, producing cytokines, and inducing
degranulation of mast cells. Loss of SphK2 reduced mast cell degranulation by 60%, and calcium ion signaling in
SphK2-deficient mast cells was impaired. Meanwhile, increased intracellular calcium ion levels rescued the degran-
ulation defect. Absence of SphK2 prevented translocation of protein kinase C to the cell membrane and NF-kB
activation. In contrast, mice lacking SphK1 had reduced amounts of circulating S1P and a defect in the anaphylaxis
response. These anaphylaxis-resistant SphK1-deficient mice had low concentrations of circulating S1P, but mast
cell degranulation was normal indicating that their mast cells are functional. Thus, it appears that although both
kinases regulate allergic responses, SphK1 is unexpectedly an extrinsic regulator important for anaphylaxis and
controlling levels of circulating S1P, whereas SphK2 is an intrinsic regulator of mast cells.
A. Olivera et al. (2007). Immunity 26, 287–297. Published online March 8, 2007. 10.1016/j.immuni.2007.02.008.
In the Fight against Allergies, Steroids Reign Supreme
Regulatory T cells (Tregs) suppress immune responses including
allergic responses mediated by Th2 cells. Signaling through the
glucocorticoid-induced tumor necrosis factor receptor related pro-
tein (GITR), which is expressed by Tregs, alleviates Treg-mediated
suppression of the immune system. The ligand of this receptor,
GITRL, is present on dendritic cells including plasmacytoid
dendritic cells (pDCs), a specialized population of dendritic cells
that produce large amounts of type I interferon. Grohmann et al.
(2007) reveal that reverse signaling via GITRL counteracts signaling
via membrane-bound GITR in mice. They find that pDCs express
GITRL, which—upon stimulation with GITR—activates indole-
amine 2, 3-dioxygenase (IDO). This enzyme catabolizes trypto-
phan, an essential amino acid, thereby suppressing growth. They
also show that activation of IDO depends on the noncanonical
NF-kB pathway. When administered to mice, the glucocorticoid
dexamethasone induced the expression of GITR by CD4+ T cells
and GITRL by pDCs. In an experimental mouse model of allergic
bronchopulmonary aspergillosis (a Th2-mediated allergic response), treatment of mice with dexamethasone re-
duces the symptoms in an IDO-dependent manner. Thus, the GITRL-dependent modulation of tryptophan catabo-
lism could be one way in which glucocorticoids alleviate symptons of allergy.
Although topical application of glucocorticoids are known to alleviate symptoms of contact allergies, such as
those generated upon contact with poison ivy, it is not clear which cells they target and how they mediate their
effects. Glucocorticoids suppress many kinds of genes encoding inflammatory molecules including cytokines
and chemokines. Their effects are mediated through the glucocorticoid receptor (GR), a nuclear hormone receptor.
Tuckermann et al. (2007) induced contact hypersensitivity in amousemodel of human contact allergy and found that
dexamethasome treatment did not affect the allergic response during the first exposure to the allergen (the
sensitization phase). However, treatment with dexamethasone 1 hr before reapplication of the contact allergen,
i.e., during the challenge phase, prevented the inflammatory response. Which cell types are sensitive to glucocor-
ticoid action? Using GRmutant mice, the authors found that dexamethasone did not suppress the immune response
when contact hypersensitivity was induced in the absence of GR in myeloid cells (macrophages and neutrophils).
The authors go on to show that dimerization of GR and the ability of the dimer to bind to DNA and presumably
activate transcription are required for dexamethasone to suppress the immune response. The authors show that
dexamethasone treatment prevents production of several cytokines and chemokines by macrophages and neutro-
phils that normally induce leukocytes to migrate the site of contact. This study indicates how dexamethasone helps
to suppress inflammation in response to contact allergens.
U. Grohmann et al. (2007). Nat. Med. 13, 579–586. Published online April 8, 2007. 10.1038/nm1563.
J.P. Tuckermann et al. (2007). J. Clin. Invest. 117, 1381–1390. Published online April 19, 2007. 10.1172/JCI28034.
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